MONALEESA-3 Data Highlight Ribociclib as Standard in HR+ Breast Cancer
Dennis J. Slamon, MD, PhD, discusses how the MONALEESA-3 results have shifted the understanding of therapy placement in women with HR-positive, HER2-negative advanced breast cancer.
Source: OncLive